A diagnostic biomarker technology for distinguishing Crohn's disease from ulcerative colitis in inflammatory bowel disease

Background

Inflammatory bowel disease (IBD) is a chronic condition that primarily includes Crohn’s disease (CD) and ulcerative colitis (UC), both of which cause significant gastrointestinal inflammation and morbidity. Accurate differentiation between CD and UC is crucial, as these diseases have distinct pathological features, prognoses, and treatment strategies. However, the clinical manifestations of CD and UC often overlap, making it challenging for healthcare providers to distinguish between them based solely on symptoms, endoscopic findings, or histopathological examination. As a result, there is a pressing need for reliable biomarkers that can aid in the precise diagnosis and classification of IBD subtypes, thereby enabling more targeted and effective patient management.

Current diagnostic approaches for differentiating CD from UC rely heavily on a combination of clinical assessment, imaging studies, endoscopy, and histology. Despite advances in these techniques, a significant proportion of IBD cases remain indeterminate, leading to delays in diagnosis and suboptimal treatment. Existing biomarkers, such as C-reactive protein (CRP) and fecal calprotectin, are useful for detecting general inflammation but lack the specificity required to distinguish between CD and UC. Additionally, many immunohistochemical markers and genetic tests have shown limited sensitivity or specificity, and some require invasive tissue sampling. These limitations highlight the need for novel, non-invasive, and highly specific diagnostic tools that can accurately differentiate between CD and UC to guide appropriate therapeutic decisions.

Technology

This technology is a diagnostic solution designed to accurately distinguish between Crohn’s disease (CD) and ulcerative colitis (UC), the two main forms of inflammatory bowel disease (IBD). It operates by quantifying the DEFA5 protein or its gene expression in biological samples such as stool, blood, tissue, or serum. Central to the solution is an anti-DEFA5 antibody that has been engineered for high specificity, ensuring it binds only to the DEFA5 protein and not to closely related defensins like DEFA1 or DEFA6. The process involves comparing the measured DEFA5 levels to a predetermined benchmark: elevated levels indicate the presence of DEFA5-secreting Paneth cells in the colon, which is a hallmark of CD, while lower levels suggest UC. The technology is delivered as a kit that includes the specialized antibody and the necessary tools for sample collection, streamlining the diagnostic workflow for clinicians.

What differentiates this technology is its precision and reliability in differentiating between CD and UC, conditions that often present with overlapping symptoms but require distinct treatment strategies. Traditional diagnostic methods, such as endoscopy and histopathology, can be invasive, time-consuming, and sometimes inconclusive. By leveraging the unique expression pattern of DEFA5 in CD, this solution provides a minimally invasive, rapid, and highly specific diagnostic alternative. The engineered antibody’s high specificity reduces the risk of false positives and negatives that can arise from cross-reactivity with other defensins, enhancing diagnostic accuracy. This targeted approach not only improves patient outcomes by enabling tailored treatment but also represents a significant advancement in the molecular diagnosis of IBD.

Benefits

• Accurate differentiation between Crohn’s disease and ulcerative colitis using DEFA5 biomarker levels
• Minimized cross-reactivity due to highly specific anti-DEFA5 antibody
• Non-invasive testing possible with various biological samples (stool, blood, tissue, serum)
• Enables targeted and appropriate treatment decisions based on precise diagnosis
• Facilitates early and reliable diagnosis of inflammatory bowel disease subtypes
• Can be implemented as a convenient diagnostic kit for clinical use

Applications

• IBD subtype diagnostic kits
• Personalized IBD treatment planning
• Point-of-care IBD testing
• Clinical laboratory diagnostic services

Additional info

This diagnostic system employs DEFA5 protein or gene expression as a biomarker to differentiate Crohn’s disease from ulcerative colitis. It quantifies DEFA5 levels in biological samples using a highly specific anti-DEFA5 antibody, engineered to minimize cross-reactivity. Elevated DEFA5 indicates Crohn’s disease, facilitating accurate inflammatory bowel disease classification and informing targeted therapies.